N-(tert-butoxycarbonyl)phenylglycine methyl ester | 1393644-14-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(tert-butoxycarbonyl)phenylglycine methyl ester
• 英文别名: methyl 2-[N-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetate
• CAS: 1393644-14-8
• 化学式: C₁₄H₁₉NO₄
• 分子量: 265.309
• InChiKey: NFRDVCYOAVGICX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl)phenylglycine methyl ester 在 一水合肼 作用下， 以 乙醇 为溶剂， 以91%的产率得到tert-butyl (2-hydrazineyl-2-oxoethyl)(phenyl)carbamate
  参考文献：
  名称：

  Discovery and optimization of novel fatty acid transport protein 1 (FATP1) inhibitors

  摘要：

  The discovery, optimization and structure-activity relationship of novel FATP1 inhibitors have been described. The detailed SAR studies of each moiety of the inhibitors combined with metabolite analysis led to the identification of the potent inhibitors 11p and 11q with improved blood stability. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.130
• 作为产物：
  描述：

  N-Boc-苯胺 、 溴乙酸甲酯 在 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 以61%的产率得到N-(tert-butoxycarbonyl)phenylglycine methyl ester
  参考文献：
  名称：

  Discovery and optimization of novel fatty acid transport protein 1 (FATP1) inhibitors

  摘要：

  The discovery, optimization and structure-activity relationship of novel FATP1 inhibitors have been described. The detailed SAR studies of each moiety of the inhibitors combined with metabolite analysis led to the identification of the potent inhibitors 11p and 11q with improved blood stability. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.130

文献信息

• Isoquinoline compounds
  申请人：deLong A. Mitchell

  公开号：US20070142429A1

  公开（公告）日：2007-06-21

  Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

  提供了含有G的异喹啉化合物，能够影响、抑制或减少G蛋白受体激酶的作用。同时还提供了含有治疗有效量的异喹啉化合物和药用载体的制药组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或条件，如癌症、骨质疏松和青光眼等的各种方法。
• &bgr;-amino-&agr;-hydroxycarboxylic acid derivatives and HIV protease inhibitors
  申请人：Japan Energy Corporation

  公开号：US06313094B1

  公开（公告）日：2001-11-06

  &bgr;-Amino-&agr;-hydroxycarboxylic acid derivatives represented by the following formula and salts thereof which are useful as human immunodeficiency virus (HIV) protease inhibitors: The compounds are effective for treating a patient suffering from AIDS and AIDS related diseases.

  以下公式所代表的&bgr;-氨基-&agr;-羟基羧酸衍生物及其盐，可用作人类免疫缺陷病毒（HIV）蛋白酶抑制剂。这些化合物对于治疗患有艾滋病和艾滋病相关疾病的患者是有效的。
• ISOQUINOLINE COMPOUNDS
  申请人：deLong Mitchell A.

  公开号：US20090069371A1

  公开（公告）日：2009-03-12

  Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

  本发明提供了含有G的异喹啉化合物，其能够影响、抑制或减少G蛋白受体激酶的作用。同时还提供了包含治疗有效量的异喹啉化合物和药用载体的制药组合物。本发明还提供了使用这些化合物和/或组合物来影响癌症、骨质疏松症和青光眼等疾病状态或病情的各种方法。
• HIV protease inhibitors
  申请人：JAPAN ENERGY CORPORATION

  公开号：EP0490667A2

  公开（公告）日：1992-06-17

  Human immunodeficiency virus (HIV) protease inhibitors comprising a compound represented by the following general formula or pharmaceutically acceptable salt thereof: The inhibitors are effective for treating a patient suffering from AIDS and AIDS related diseases.

  人类免疫缺陷病毒（HIV）蛋白酶抑制剂，包括由以下通式代表的化合物或其药学上可接受的盐： 这些抑制剂可有效治疗艾滋病和艾滋病相关疾病患者。
• US6313094B1
  申请人：——

  公开号：US6313094B1

  公开（公告）日：2001-11-06